Abstract:The immune response consists of a finely-tuned program, the activation of which must be coupled with inhibitory mechanisms whenever initiated. This ensures tight control of beneficial anti-pathogen and anti-tumor responses while preserving tissue integrity, promoting tissue repair, and safeguarding against autoimmunity. A cogent example of this binary response is in the mobilization of co-stimulatory and co-inhibitory signaling in regulating the strength and type of a T-cell response. Of particular importance is the costimulatory molecule CD28 which is countered by CTLA-4. While the role of CD28 in the immune response has been thoroughly elucidated, many aspects of CTLA-4 biology remain controversial. The expression of CD28 is largely constrained to constitutive expression in T-cells and as such, teasing out its function has been somewhat simplified by a limited and specific expression profile. The expression of CTLA-4, on the other hand, while reported predominantly in T-cells, has also been described on a diverse repertoire of cells within both lymphoid and myeloid lineages as well as on the surface of tumors. Nonetheless, the function of CTLA-4 has been mostly described within the context of T-cell biology. The focus on T-cell biology may be a direct result of the high degree of amino acid sequence homology and the co-expression pattern of CD28 and CTLA-4, which initially led to the discovery of CTLA-4 as a counter receptor to CD28 (for which a T-cell-activating role had already been described). Furthermore, observations of the outsized role of CTLA-4 in T reg -mediated immune suppression and the striking phenotype of T-cell hyperproliferation and resultant disease in CTLA-4 −/− mice contribute to an appropriate T-cell-centric focus in the study of CTLA-4. Complete elucidation of CTLA-4 biology, however, may require a more nuanced understanding of its role in a context other than that of T-cells. This makes particular sense in light of the remarkable, yet limited utility of anti-CTLA-4 antibodies in the treatment of cancers and of CTLA-4-Ig in autoimmune disorders like rheumatoid arthritis. By fully deducing the biology of CTLA-4-regulated immune homeostasis, bottlenecks that hinder the widespread applicability of CTLA-4-based immunotherapies can be resolved.

Molecular and Cellular Functions of CTLA-4.

Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types

CTLA-4: From mechanism to autoimmune therapy

Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

Ctla-4-Mediated Inhibition Of Early Events Of T Cell Proliferation

B7 Interactions with CD28 and CTLA-4 Control Tolerance or Induction of Mucosal Inflammation in Chronic Experimental Colitis

Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy

CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis

Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation

The Role of the CD28 Family Receptors in T-Cell Immunomodulation

CD86 Is a Selective CD28 Ligand Supporting FoxP3+ Regulatory T Cell Homeostasis in the Presence of High Levels of CTLA-4

Taming tissue-specific T cells: CTLA-4 reins in self-reactive T cells

Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy

Altered Ligand-Interaction Contributes to Functional Insufficiency Due to CTLA-4 Gene Mutation

Understanding the cellular and molecular mechanism of anti-CTLA4 mediated tumor rejection

Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152)

Engagement of Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) Induces Transforming Growth Factor Beta (Tgf-Beta) Production by Murine CD4(+) T Cells.

The Mechanism Study on CTLA4 involved in Regulatory T cell Mediating Immune Tolerance for Xenogeneic Response

T Cell Costimulation through CD28 Depends on Induction of the Bcl-xγ Isoform

Elucidating CTLA-4's role in tumor immunity: a comprehensive overview of targeted antibody therapies and clinical developments